Kornimate/medical-research-clean huggingface dataset:
causes and management of aseptic meningitis : a retrospective cohort study in strasbourg university hospital

Conditions: Aseptic Meningitis

Summary: the diagnostic and therapeutic management of patients with aseptic meningitis is a challenge for the practitioner. there are many etiologies of this condition (infectious, inflammatory, neoplastic, drug-induced), which it is necessary to know how to evoke and look for specifically.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * subject with aseptic meningitis (csf pleocytosis, negative bacteriology) from january 2015 to october 2020, at hus * subject having not expressed, after being informed, their opposition to the reuse of their data for the purposes of this research. exclusion criteria: * subject who expressed their opposition to participating in the study * subject under guardianship or curatorship * subject under safeguard of justice * positive vzv, hsv, or enterovirus pcr in csf * csf analysis performed as part of the assessment of a known pathology * traumatic or surgical etiology

Keywords: aseptic meningitis infectious inflammatory neoplastic drug-induced
feasibility of non-pharmacological insomnia therapy in people living with hiv

Conditions: Insomnia; Sleep Efficiency

Summary: to establish with a prospective randomized placebo-controlled study the feasibility of allied-health personnel-administered cognitive behavioral insomnia therapy (cbti) as a means of improving hiv/aids treatment adherence.


Eligibility criteria:
inclusion criteria: * provide documentation of hiv seropositivity, and have been on current haart (highly active antiretroviral therapy) or antiretroviral regimen without any foreseeable reason to discontinue the haart during the course of the study; * males or females age 18-75 years of age; * ≥3 month history of insomnia meeting standard psychiatric criteria for insomnia based on dsisd; * sleep onset latency (sol) and/or wake after sleep onset (waso) greater than 30 minutes, with a corresponding sleep time of less than 6.5 hours at least 3 nights per week (as measured by the 7-day sleep diary); * be able to read, understand, and sign an informed consent form before entering into the study and must be willing to comply with all study procedures as well as to agree to participate for the entire study period. exclusion criteria: * use of any medication with a significant effect on sleep/wake function within 5 half-lives of baseline or during the study including hypnotics, over-the-counter sleep aides, sedating antidepressants or sedating anxiolytics; * history or dsisd (duke insomnia sleep diagnostics) suggests sleep disorder other than insomnia (e.g., sleep apnea, narcolepsy, periodic leg movements, etc.), or have insomnia associated with circadian rhythm disturbances, such as night or rotating shift work or travel across more than four time zones in the 14 days before initial screening (visit 1) or during the study; * clinically significant unstable medical or psychiatric condition, or have any clinically significant abnormal finding in physical examination, neurological assessment, or vital signs, as determined by the investigator; * self reports typical consumption of more than five alcoholic beverages on a single day or greater than 14 alcoholic beverages weekly at initial screening (visit 1); * have used any investigational drug within 30 days or five half-lives (whichever is longer) prior to initial screening (visit 1), or plans to use an investigational drug during the study; * unable to give informed consent or comply with study procedures.

Keywords: haart adherence hiv fatigue treatment
sucralose, stevia, gut microbiome and glucose metabolism

Conditions: Impaired Glucose Tolerance

Summary: this study will determine the influence of two non-caloric sweeteners on glucose metabolism via the gut microbiome in adult men and women.

this study will determine the influence of two non-caloric sweeteners on glucose metabolism via the gut microbiome in adult men and women aged 35-55 years.

Eligibility criteria:
inclusion criteria: generally health adult men and women aged 35-55 years old - exclusion criteria:adults will not be eligible who have chronic disease (cancer, chd, diabetes, chronic kidney disease); pregnant or breast feeding; menopausal; has a history of bariatric surgery; taking prednisone/steroids, taking medication for pcos, or take medications that influence blood glucose. -
ventripoint single ventricle study

Conditions: Congenital Heart Disease; Single-ventricle

Summary: this study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles.

the accuracy of current echocardiographic techniques for measuring ventricular size and function are limited by geometric assumptions, which are particularly problematic in malformed hearts or functional single ventricles, as well as the inability to visualize the entire heart at one time from a single imaging window, and higher heart rates degrading 3d imaging volume rates. this study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles, including a comparison to the gold standard of cardiac mri.

Eligibility criteria:
inclusion criteria: * all patients with functional single ventricles will be included, regardless of age or surgical palliation stage, who have had or are having a clinically ordered transthoracic echocardiogram and/or cardiac mri. exclusion criteria: * patients with congenital heart disease other than functional single ventricles, patients with single ventricle physiology (but not single ventricle anatomy) following a biventricular conversion pathway, or patients unable to understand or consent in english will be excluded.
real-world incidence of intraocular inflammation following intravitreal faricimab therapy

Conditions: Intraocular Inflammation

Summary: faricimab (vabysmo®), a novel pharmaceutical agent is a promising treatment for age-related macular degeneration and diabetic macular edema due to its dual mechanism of action, targeting both the vegf and angiopoietin-2 (ang-2) pathways, offering potential benefits in improving visual outcomes and reducing treatment burdens. the phase 3 tenaya and lucerne clinical trials have demonstrated its efficacy and safety profile, leading to regulatory approval and increasing use in clinical practice. however, as with any new therapeutic agent, there is a critical need to monitor and evaluate real-world safety data to complement and validate clinical trial findings. intraocular inflammation (ioi), which is a significant adverse effect of intravitreal anti-vegf injections, is of particular interest as it can vary from a mild transient reaction to a potentially vision-threatening outcome. the incidence and severity of ioi in a real-world settings can vary from clinical trial results due to differences in patient populations, injection techniques, and clinical settings. the aim of this study is to estimate the real-life incidence of intraocular inflammation following intravitreal faricimab injections at a large, regional highly specialized tertiary center.


Eligibility criteria:
inclusion criteria * \>18 years of age * having received at least 1 intravitreal faricimab injection at our center * follow-up period of at least 6 weeks after the injection exclusion criteria for ioi cases * having received intravitreal injections of other types (e.g., intravitreal steroids, antiviral agents) at the same time as the intravitreal anti-vegf injection or during the follow-up period * underwent intraocular surgery within 6 weeks before or after the intravitreal injection, except for surgical interventions that are meant to diagnose or treat the actual ioi in question (e.g., diagnostic chamber tap, diagnostic vitrectomy, vitrectomy for suspected endophthalmitis, etc.)

Keywords: faricimab intravitreal injection anti-vegf intraocular inflammation
low-cost tool for compliance and treatment-tracking of low back pain patients

Conditions: Low Back Pain

Summary: the purpose of the study is to develop, design and implement an easy-to-use, cloud-enabled software for patients with low back pain and evaluate the effect of the system on compliance and quality of life. the investigators hypothesize that a device which measures compliance to physical therapy regimens in patients with low back pain will increase patient participation.

innovative design labs (idl) proposes to develop and deploy a low-cost measurement system which tracks exercise compliance and enables remote health coaching for patients with low back pain. the system will consist of a series of small motion sensors built into a custom designed harness which connect wirelessly to the user's tablet or smartphone. a software application will guide the patient through the exercise routine while the sensor system monitors their motion, classifies exercise completion, and tracks their progress through the protocol. the results of the routine will be securely uploaded to caregivers where they can monitor progress, modify the patient's exercise prescription, and offer encouragement and coaching to continue the therapy. this research program aims to enable the long term treatment-tracking of patients with chronic low back pain.

Eligibility criteria:
inclusion * 18 years or older * diagnosis of chronic low back pain (\> 3 months duration) * have a current prescription for at-home exercises for chronic low back pain exclusion * patients with a high likelihood of being lost to follow-up or contact * patients with an inability to provide good data or follow commands * patients with an inability to do mild exercise * patients with a history of spine surgery that included instrumentation or hardware * patients who are taking opioid medication chronically without reasonable reduction in pain

Keywords: exercise compliance health coaching
the facial muscular activity: a paradigm for understanding facial asymmetry

Conditions: Facial Asymmetry

Summary: facial asymmetry, the degree to which the two sides of the face differ in size, shape, or the arrangement of features, is a near-universal human characteristic. the intricate network of facial muscles plays a crucial role in both the static structure and the dynamic expressions of the face. the continuous pull and action of facial muscles can influence the development and positioning of underlying soft tissues and even, over extended periods, potentially impact skeletal structures.


Eligibility criteria:
inclusion criteria: * presenting with noticeable facial asymmetry * age \> 16 years * general good health * absence of specific neurological conditions affecting facial muscles. * absence of congenital facial disorders that might cause facial asymmetry, like hemifacial microsomia and cleft lip and palate syndromes. exclusion criteria: * history of facial trauma or surgery * diagnosed neuromuscular disorders * active facial infections.
addition of a topical steroid to a topical retinoid in acne patients

Conditions: Acne

Summary: a randomized, split-face, placebo-controlled, double-blind, single-center clinical trial comparing topical retinoid on half the face and retinoid plus topical steroid on the other half.

a randomized, split-face, placebo-controlled, double-blind, single-center clinical trial wherein 20 patients received daily 0.05% tretinoin with one half of the face receiving triamcinolone 0.025% and the other half an inert emollient for 4 weeks. subjects continued applying tretinoin 0.05% daily to the bilateral face without triamcinolone or emollient for an additional 4 weeks. investigator's global assessment, lesion counts, and study subject's self-assessments of burning/stinging, itching, erythema, and dryness/scaling will be collected at 1, 2, 4, and 8 weeks.

Eligibility criteria:
inclusion criteria: * fitzpatrick skin types i, ii, or iii * will and ability to discontinue use of topical medicines on the face for study duration * capability to understand and provide informed consent exclusion criteria: * use of oral retinoids within previous 6 months * use of corticosteroids on the face or systemic corticosteroids within previous 4 weeks * any additional facial skin condition (i.e., rosacea, seborrheic dermatitis, etc.) * female participants who are pregnant, nursing, or planning pregnancy while participating in the study * hypersensitivity to ingredients in study formulations * existence of an underlying condition that an investigator feels would hinder a participant's ability to complete the study or appropriately follow directions

Keywords: tretinoin topical steroid irritation retinoid induced irritation
adapting and evaluating a tobacco use cessation program for people living with hiv in uganda and zambia

Conditions: Nicotine Dependence; Tobacco Dependence

Summary: this proposal tests the efficacy of a phone-based tobacco cessation intervention for people living with hiv (plwh) in comparison to the standard of care (brief advice to quit) and nicotine replacement therapy (nicotine patches) in uganda and zambia. this study will provide insight into the efficacy, feasibility, applicability, and affordability of delivering tobacco cessation interventions through health care professionals at hiv treatment centers in two countries with different tobacco use patterns, policy environments, and health care resources. the previously tested sms-platform to be used in this study is uniquely positioned to be scaled in low- and middle-income countries worldwide, in which case rigorous research showing even modest success in reducing the prevalence of tobacco consumption among plwh could confer substantial health and economic benefits.

while there is substantial evidence supporting interventions to help tobacco users in the general population quit, little is available relevant to the challenges facing hiv+ tobacco users, especially those living in low-income african countries. this study approaches this gap with the first randomized control trial (rct) to test the efficacy of a tailored short message service (sms) based tobacco use cessation intervention on prolonged tobacco use abstinence at 6 months post program initiation in comparison to the standard of care (brief advice to quit) and nicotine replacement therapy (nicotine patches) among plwh in uganda and zambia. this study will provide insight into the efficacy, feasibility, applicability, and affordability of delivering tobacco cessation interventions through health care professionals at hiv treatment centers in two countries with different tobacco use patterns, policy environments, and health care resources and provide needed information to providers and policymakers looking for cost-effective tobacco cessation interventions.

Eligibility criteria:
inclusion criteria: - exclusion criteria: * females who are pregnant, planning to get pregnant, or breastfeeding * \<18 years (underage of consent) * visitor, not receiving continuous care at study site * not a current daily tobacco user * any physical, cognitive, or psychological disabilities that would prevent them from participating in the study * illiterate in english and/or local languages * does not consent
evaluation of hrct patterns in systemic sclerosis-associated interstitial lung disease

Conditions: Systemic Sclerosis; Interstitial Lung Disease

Summary: systemic sclerosis (ssc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. interstitial lung disease (ild) concerns almost 50 % of ssc patients and represents the main cause of mortality. ssc-ild is variable: from limited forms (with asymptomatic patients) to extensive lesions. disease course in ssc-ild is also highly variable: patients can experience stable disease, slow or fast progression. investigators performed unsupervised clustering analysis to classify ssc-ild according to elementary radiological lesions on hrct scan.


Eligibility criteria:
inclusion criteria: * patients with systemic sclerosis according to 2013 acr/eular criteria * patients with interstitial lung disease on hrct chest exclusion criteria: * patients with an alternative diagnosis of ssc-associated ild (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)
evaluating patient and caregiver satisfaction with the informed consent process in surgery

Conditions: Informed Consent; Patient and Caregiver Satisfaction

Summary: the goal of this observational study is to evaluate patient and caregiver satisfaction with the informed consent process in surgical practice at a tertiary care center in nepal. the main questions it aims to answer are: how satisfied are patients and caregivers with the current informed consent process in surgery? how well do patients and caregivers understand the informed consent information provided? are there differences in satisfaction and understanding based on factors such as education level or family involvement? researchers will compare the perceptions of patients and caregivers to understand if there are gaps in communication and satisfaction. participants will: complete a structured questionnaire assessing their understanding and satisfaction with the informed consent process. share their views on the type and quality of information provided during the consent process. rate their satisfaction on a 10-point scale based on their experience with the informed consent procedure.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older undergoing major elective surgical procedures requiring regional or general anesthesia. * caregivers of eligible patients who provide informed consent on behalf of the patient. * willingness to participate and provide consent for the study. exclusion criteria: * patients undergoing emergency surgeries. * patients who are unable to participate due to language barriers or cognitive impairment. * patients or caregivers who refuse to participate in the study.
community screening study of diabetic retinopathy in tianjin in 2024

Conditions: Diabetic Retinopathy

Summary: through this study, the investigators hope to understand the prevalence and influencing factors of diabetic retinopathy in tianjin, improve the ability of complication detection and intervention in diabetic patients in primary medical and health institutions, and build a diabetes prevention and treatment network. the investigators should adhere to the policy of prevention first, combined with prevention and control, and explore a diabetes' prevention and control model suitable for our city. extensive publicity and education should be carried out to improve the awareness of self-management ，improve the screening rate of diabetic retinopathy, and reduce the blindness rate.

west of the city, and hebei, heping and binhai new area to carry out the work, diabetic retinopathy screening on 18000 diabetic patients in fundus examination. tianjin medical university eye hospital, project team, formed in grassroots medical institutions are responsible for screening fundus examination in patients with diabetes, related inspection including vision, computer optometry, fundus photography and optical coherence tomography angiography (octa), etc. blood samples were collected from patients in hexi district and heping district to detect glycosylated hemoglobin. glycated albumin, urine acr and co breath test were performed in chu hsien-i memorial hospital of tianjin medical university. health records were established for the screening personnel after the examination

Eligibility criteria:
inclusion criteria: - 1: clear awareness, barrier-free communication 2: diabetes exclusion criteria: * 1: have left the registered home address 2: in the last 6 months, you have not lived in your place of residence 3: have a serious mental illness

Keywords: diabetic retinopathy
study to investigate the efficacy and safety of wx-0593 in alk positive non-small cell lung cancer (nsclc) patients

Conditions: Non-small Cell Lung Cancer

Summary: the primary purpose of this study is to evaluate the efficacy and safety of wx-0593 in patients with alk-positive nsclc


Eligibility criteria:
key inclusion criteria: * ≥18 years * female or male * patient has an eastern cooperative oncology group (ecog) performance status ≤ 2 * life expectancy of at least 12 weeks * at least one measurable lesion * histologically or cytologically confirmed diagnosis of advanced or recurrent or metastatic nsclc that is alk-positive by grade a tertiary hospitals, and subjects should have disease progression (recist 1.1) or intolerance (stopping criteria according to drug insert) after 1 or 2 marketed alk inhibitors, the patients had disease progression after alk inhibitor should continuously have drug at least 12 weeks , and less than 3 chemotherapy regimens previously * no brain metastasis, or asymptomatic brain metastasis, or symptomatic brain metastasis but stable for more than 4 weeks after treatment, and have stopped systemic hormone treatment (prednisone of \> 10 mg/day or equivalent hormone) for more than 2 weeks key exclusion criteria: * crizotinib is the only alk inhibitor subjects received;unmarketed alk inhibitor received; lorlatinib or brigatinib received; active ingredient or generic drug of alk inhibitors received * hbsag-positive and/or hbcab positive and hbv dna \> 1000 copies/ml, or hcv antibody-positive, or known hiv infected
social cognition in youth who have a first degree relative with schizophrenia

Conditions: Schizophrenia

Summary: social cognition is an individual's ability to perceive, process, understand, and react to other individuals in a social situation. social cognition is impaired in individuals with schizophrenia, including difficulty recognizing others' emotions. a promising treatment avenue for emotion recognition problems in individuals with schizophrenia is continued practice with various facial expression recognition training programs. first degree relatives of someone with schizophrenia are considered at familial high risk (fhr) for the illness, because of its high level of heritability. it is therefore critical to explore if these emotion recognition training programs could also benefit people at fhr. in this current study, the investigators aim to explore the social-cognitive profiles and their neural correlates in fhr individuals. the investigators also aim to explore the potential efficacy of an emotion recognition intervention to improve this ability in fhr individuals.

all participants will complete a battery of social cognitive tests as well as an fmri scan to explore the neuronal correlates underlying lower social cognitive functioning observed in fhr individuals. fhr youth will be randomized into either a 4-session emotion recognition training exercise program on ipad or an active control training program on ipad that includes commercial games and control emotional attention bias training.

Eligibility criteria:
inclusion criteria: * between (or equal to) 15-25 years of age * ability to read/speak fluent english * diagnosis of sz, schizoaffective disorder or schizophreniform confirmed for 1st degree relative by referring psychiatrist or two reliable informants (using the adapted figs questionnaire). exclusion criteria: * diagnosis of mental health disorder * significant neurological or medical disorders that may produce cognitive impairment * current epilepsy or previous history of seizures * previous head injury with current continuing symptoms (i.e., cognitive ability, dizziness, etc.) * recent history of substance abuse or dependence (within past 3 months) * mri contraindication (e.g. metallic head implant, history of seizure, pacemaker, pregnancy, etc.) * current iq \< 70 as measured by the wechsler abbreviated scale of intelligence scale (wasi)